Halozyme Therapeutics reported $56.53M in Operating Profit for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
Agios Pharmaceuticals AGIO:US $ -102.18M 13.03M
Aptinyx Inc APTX:US $ -19379000 207K
Cytokinetics CYTK:US $ -80.55M 58.85M
Immunogen IMGN:US $ -22.85M 11.7M
Intrexon XON:US $ -25.47M 9.8M
IONIS PHARMACEUT IONS:US $ 221M 306.85M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Nektar Therapeutics NKTR:US $ -112.91M 0.69M
Peregrine Pharmaceuticals PPHM:US $ 4.15M 2.78M